London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

"GSK acquires efimosfermin alfa from Boston Pharma for $2bn" was originally created and published by Pharmaceutical ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to ...

Four co-authors are employees of Boston Pharmaceuticals, and one now consults for Boston Pharmaceuticals after being employed there during this study. One other co-author reported various industry ...

Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later ...

Rhythm Pharmaceuticals, Inc. may be ripe in a year. At that time, setmelanotide should be approved for HO in the U.S. and ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

The Boston Arts Academy Foundation closed its Building Our Future fundraising campaign, surpassing its $35 million goal, ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

A Cambridge biotech company is preparing to lay off its entire staff of more than 300 after being acquired by another firm.